By a News Reporter-Staff News Editor at Gene Therapy Weekly -- New research on Health and Medicine is the subject of a report. According to news reporting originating in San Diego, California, by NewsRx journalists, research stated, "The Esophageal cancer-related gene-4 (Ecrg4) is a candidate tumor suppressor gene whose secreted protein product has been implicated in the development and progression of epithelial cancers, neuroprogenitor cell activation after central nervous system injury, cell senescence in neurodegeneration, and the survival of hematopoietic stem cells. Here, we investigated the temporal and spatial localization of Ecrg4 expression in healthy and injured mouse skin, and evaluated the biological activity of Ecrg4 using viral-mediated gene delivery in cutaneous wound healing models."
The news reporters obtained a quote from the research from the University of California School of Medicine, "Using in situ hybridization and immunohistochemistry, we found both Ecrg4 mRNA and its protein product localized to the epidermis, dermis, and hair follicles of healthy mouse skin. Upon cutaneous injury, Ecrg4 redistributed to the wound margins where gene microarray and quantitative RT-PCR showed an increased gene expression 5-10 days post-injury as a late phase injury response gene. Ecrg4 over-expression inhibited the directional migration of fibroblasts in modified Boyden chambers in vitro, but had no effect on rates of fibroblast proliferation. Ecrg4 over-expression in vivo at the wound margins delayed the rate of wound closure at 1 and 2 days after full-thickness punch injury. These findings point to the candidate tumor suppressor gene Ecrg4 as a novel, biologically active, constituent of skin and skin injury."
According to the news reporters, the research concluded: "The possibility that Ecrg4 serves as a wound termination factor during wound resolution is discussed."
For more information on this research see: The candidate tumor suppressor gene Ecrg4 as a wound terminating factor in cutaneous injury. Archives of Dermatological Research, 2013;305(2):141-9. (Springer - www.springer.com; Archives of Dermatological Research - www.springerlink.com/content/0340-3696/)
Our news correspondents report that additional information may be obtained by contacting A. Shaterian, Division of Trauma, Surgical Critical Care and Burns, Dept. of Surgery, University of California San Diego School of Medicine, 212 Dickinson Street, San Diego, CA 92103, United States. Additional authors for this research include S. Kao, L. Chen, L.A. DiPietro, R. Coimbra, B.P. Eliceiri and A. Baird (see also Health and Medicine).
Keywords for this news article include: Biotechnology, Oncology, San Diego, California, Gene Therapy, United States, Bioengineering, Tumor Suppression, Health and Medicine, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC